IKNA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IKNA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Ikena Oncology's annualized ROCE % for the quarter that ended in Sep. 2024 was -32.09%.
The historical data trend for Ikena Oncology's ROCE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ikena Oncology Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
ROCE % | -29.98 | -44.13 | -18.93 | -38.18 | -45.90 |
Ikena Oncology Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
ROCE % | Get a 7-Day Free Trial | -43.85 | -46.87 | -36.76 | -38.83 | -32.09 |
Ikena Oncology's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:
ROCE % | = | EBIT | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | -75.417 | / | ( ( (172.259 - 21.503) | + | (192.092 - 14.205) ) | / 2 ) | |
= | -75.417 | / | ( (150.756 | + | 177.887) | / 2 ) | |
= | -75.417 | / | 164.3215 | ||||
= | -45.90 % |
Ikena Oncology's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:
ROCE % | = | EBIT (1) | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(Q: Sep. 2024 ) | (Q: Jun. 2024 ) | (Q: Sep. 2024 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(Q: Sep. 2024 ) | (Q: Jun. 2024 ) | (Q: Sep. 2024 ) | |||||
= | -46.38 | / | ( ( (157.485 - 8.196) | + | (148.988 - 9.24) ) | / 2 ) | |
= | -46.38 | / | ( ( 149.289 | + | 139.748 ) | / 2 ) | |
= | -46.38 | / | 144.5185 | ||||
= | -32.09 % |
(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ikena Oncology (NAS:IKNA) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Thank you for viewing the detailed overview of Ikena Oncology's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Owen Hughes | director | C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139 |
Jotin Marango | officer: CFO & Head of Corp. Dev. | C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3 |
Francisco Oliveira | officer: Principal Accounting Officer | IKENA ONCOLOGY, INC., 645 SUMMER STREET, SUITE 101, BOSTON MA 02210 |
Richard Wooster | director | C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421 |
Xiaoyan Michelle Zhang | officer: Chief Scientific Officer | C/O IKENA ONCOLOGY, INC., 645 SUMMER STREET SUITE 101, BOSTON MA 02210 |
Jean Francois Formela | director | C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451 |
Atlas Venture Fund Xi, L.p. | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Maria Koehler | director | C/O REPARE THERAPEUTICS INC., 7210 FREDERICK-BANTING, SUITE 100, ST-LAURENT A8 H4S 2A1 |
Orbimed Advisors Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
David P Bonita | director | C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Mark Manfredi | director, officer: President & CEO | C/O IKENA ONCOLOGY, INC., 50 NORTHERN AVENUE, BOSTON MA 02210 |
Maude Tessier | officer: Chief Business Officer | C/O IKENA ONCOLOGY, INC., 50 NORTHERN AVENUE, BOSTON MA 02210 |
Jeffrey Ecsedy | officer: Chief Scientific Officer | C/O IKENA ONCOLOGY, INC., 50 NORTHERN AVENUE, BOSTON MA 02210 |
Atlas Venture Associates Xi, L.p. | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Atlas Venture Associates Xi, Llc | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
From GuruFocus
By PurpleRose PurpleRose • 08-11-2022
By sperokesalga sperokesalga • 05-15-2023
By Marketwired • 05-13-2024
By sperokesalga sperokesalga • 04-17-2023
By GuruFocus Research • 02-07-2024
By Value_Insider Value_Insider • 11-10-2022
By Value_Insider Value_Insider • 11-28-2022
By sperokesalga sperokesalga • 05-24-2023
By Value_Insider Value_Insider • 10-18-2022
By GuruFocus Research • 02-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.